Novartis AG
A global medicines company that researches, develops, and markets healthcare products.
NOVN | SW
Overview
Corporate Details
- ISIN(s):
- CH0012005267 (+10 more)
- LEI:
- 5493007HIVTX6SY6XD66
- Country:
- Switzerland
- Address:
- LICHTSTR. 35, 4056 BASEL
- Website:
- https://www.novartis.com/
- Sector:
- Manufacturing
Description
Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-08-07 08:30 |
Obvestilo o spremembi pomembnega deleža družbe Sandoz AG
|
Slovene | 2.2 MB | ||
| 2023-08-07 08:30 |
Obvestilo o spremembi pomembnega deleža družbe Novartis Pharma AG
|
Slovene | 4.4 MB | ||
| 2023-08-07 08:30 |
Obvestilo o spremembi pomembnega deleža
|
Slovene | 2.4 KB | ||
| 2019-10-22 08:00 |
Novartis delivered another strong quarter with double digit sales growth and co…
|
English | 138.9 KB | ||
| 2019-10-08 08:15 |
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gai…
|
English | 28.9 KB | ||
| 2019-10-02 08:15 |
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing…
|
English | 21.0 KB | ||
| 2019-09-29 17:30 |
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3…
|
English | 25.3 KB | ||
| 2019-09-17 08:15 |
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indic…
|
English | 24.4 KB | ||
| 2019-08-30 08:15 |
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-hea…
|
English | 24.4 KB | ||
| 2019-07-29 08:00 |
Novartis provides update on Phase III PARAGON-HF trial in heart failure patient…
|
English | 29.7 KB | ||
| 2019-07-18 08:00 |
Novartis delivers strong sales, double digit core operating income growth and l…
|
English | 137.7 KB | ||
| 2019-07-01 18:30 |
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic p…
|
English | 19.0 KB | ||
| 2019-06-07 08:00 |
Novartis announces new leader of Pharmaceuticals Business Unit
|
English | 18.1 KB | ||
| 2019-04-24 08:00 |
Novartis starts 2019 with strong sales and double digit core1 operating income …
|
English | 95.6 KB | ||
| 2019-03-27 00:35 |
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to…
|
English | 27.7 KB |
Automate Your Workflow. Get a real-time feed of all Novartis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Novartis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Novartis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-30 | N/A | Executive member | Sell | None | 1,973,993.83 CHF |
| 2025-03-07 | N/A | Non-Executive member | Buy | None | 160,000.00 CHF |
| 2025-02-11 | N/A | Executive member | Sell | None | 312,203.18 CHF |
| 2025-02-07 | N/A | Executive member | Sell | None | 2,500,278.74 CHF |
| 2025-02-05 | N/A | Executive member | Sell | None | 1,365,687.19 CHF |
| 2025-02-04 | N/A | Executive member | Sell | None | 1,840,201.00 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 699,424.74 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 698,883.18 CHF |
| 2024-12-19 | N/A | Executive member | Sell | None | 1.00 CHF |
| 2024-11-29 | N/A | Executive member | Sell | None | 167,294.98 CHF |
Peer Companies
